TFBS Bioscience and Tottori University Announce Business Alliance for Manufacturing of Next-Generation Oncolytic Virus for Cancer Treatment

Taipei, Taiwan — 8, December 2025

TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan, hereinafter "TFBS") and the National University Tottori University (Headquarters: Tottori City, Tottori Prefecture, Japan, hereinafter "Tottori University") have entered into a business alliance (hereinafter, "the Alliance") regarding the manufacturing of the next-generation vaccinia virus, FUVAC121, developed by Professor Takafumi Nakamura and his team at the Faculty of Medicine, Tottori University. The Alliance aims to advance the future development, commercialization, and practical application of FUVAC121.

The next-generation vaccinia virus FUVAC121, developed by Professor Takafumi Nakamura and his team at the Faculty of Medicine, Tottori University, possesses an extremely high therapeutic effect, causing complete regression of not only local tumors at the administration site but also distant tumors. It features an innovative mechanism of action, including the ability to restore sensitivity to immune checkpoint inhibitor-resistant tumors.

TFBS Bioscience as a Contract Development and Manufacturing Organization (CDMO) compliant with GMP standards for viral vector products, will undertake the manufacturing of the vaccinia virus FUVAC121 at its GMP facility under this Alliance.

A contract signing ceremony for the consignment of services under this Alliance will be held on Monday, December 22, 2025, at the Tottori Campus of Tottori University. Details regarding this contract signing ceremony are available in the following press release.